Table 1. Main characteristics of the studies included in the meta-analysis.
| Study | Country | Patients (B+; B-C-/B+C-/ B-C+/B+C+) † | Controls (B+; B-C-/ B+C-/ B-C+/B+C+) | Age | Male (%) | Se% | Sp% |
|---|---|---|---|---|---|---|---|
| Xu et al.2011 | China | 101 (76; NR) | 89 a (0) | 50 | 77 | 84 | 73.5 |
| Tomimaru et al. (1) 2012 | Japan | 126(28; 14/25/84/3) | 50 a (0) | 63 | 79 | 87.3 | 92.0 |
| Tomimaru et al. (2) 2012 | Japan | 126(28;14/25/84/3) | 30 b (4; 0/4/26/0) | 63 | 79 | 61.1 | 83.3 |
| Liu et al. 2012 | China | 57 (57; NR) | 59 c (29; NR) | 60 | 71 | 89.47 | 71.19 |
| Qin et al. (1) 2013 | China | 55(21; 9/15/25/6) | 50 a (0) | 64 | 55 | 89 | 95 |
| Qin et al. (2) 2013 | China | 55(21; 9/15/25/6) | 60 b (25; 0/25/35/0) | 64 | 55 | 65 | 85 |
† B−, B+, C−, and C+ represent negative HBs-Ag, positive HBs-Ag, negative anti-HCV Ab, and positive anti-HCV Ab, respectively.
a, healthy control group;
b, control group with chronic hepatitis;
c, non-cancerous control group (healthy and chronic hepatitis B carriers).
Age, mean or median age of HCC patients; Male, men with HCC; Se, sensitivity; Sp, specificity;NR = not report.